"Turkey is still relatively new to mining but there are a lot of reserves and after the privatization drive, the industry grew rapidly. However, we still do not have a high enough level of exploration and there are social and environmental problems, which means it is difficult to get permits."
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.